Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) common stock between November 6, 2024 and August 6, 2025, inclusive (the “Class Period”).
Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Lantheus’ key Radiopharmaceutical Oncology product is PYLARIFY, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lantheus provided investors with misleading statements concerning the true state of PYLARIFY’s competitive position, notably, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for PYLARIFY; (2) Lantheus failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking PYLARIFY's price point, revenue, and overall growth potential; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On December 9, 2025, the Court appointed Lead Plaintiff and Lead Counsel. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.